Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purepac Gabapentin 180-Day Exclusivity Award “Reasonable,” Judge Says

Executive Summary

FDA's determination that Purepac is eligible for 180-day generic exclusivity on gabapentin capsules (Pfizer's Neurontin) was reasonable and "an appropriate application of administrative discretion," D.C. federal court Judge Ellen Segal Huvelle ruled April 25

You may also be interested in...



Purepac’s Neurontin Generic Exclusivity, FDA’s “Section viii” Policy Affirmed

FDA's position on the appropriate use of "section viii" statements in ANDAs will stand following an appellate court ruling on gabapentin generics

Purepac’s Neurontin Generic Exclusivity, FDA’s “Section viii” Policy Affirmed

FDA's position on the appropriate use of "section viii" statements in ANDAs will stand following an appellate court ruling on gabapentin generics

Neurontin, Rebetol Generics Could Be Affected By “Shared Exclusivity” Ruling

A federal court decision invalidating FDA's "shared exclusivity" policy for first-to-file ANDAs poses another potential complication to the launch of generic versions of Pfizer's Neurontin (gabapentin)

Related Content

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel